The Heart -- The Food and Drug Administration has approved tolvaptan (Samsca, Otsuka America Pharmaceuticals), a selective vasopressin-receptor antagonist that can be taken orally, for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia, including patients with heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion.
